Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.16 | 7e-06 |
mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.14 | 8e-05 |
mRNA | BRD-K61166597 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0004 |
mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.001 |
mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.001 |
mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | -0.099 | 0.002 |
mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | -0.16 | 0.002 |
mRNA | Vorinostat | GDSC1000 | pan-cancer | AAC | -0.1 | 0.002 |
mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.12 | 0.002 |
mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | -0.12 | 0.002 |